<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00630799</url>
  </required_header>
  <id_info>
    <org_study_id>GP/C/04/PRO</org_study_id>
    <nct_id>NCT00630799</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients</brief_title>
  <official_title>Efficacy and Safety of a New Leuprolide Acetate 17 mg Depot Formulation, GP-Pharm S.A., When Given as Palliative Treatment to Prostate Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GP-Pharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GP-Pharm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label study of 2 doses of leuprolide acetate 17 mg depot,
      administered three months apart, in subjects with prostate cancer who might benefit from
      medical androgen deprivation therapy
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of successful patients achieving chemical castration</measure>
    <time_frame>Days 28, 84, and 168</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>WHO/ECOG performance status</measure>
    <time_frame>Days 14, 28, 56, 84, 112, and 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum LH concentration (mIU/mL)</measure>
    <time_frame>Days 2, 14, 28, 56, 84, 86, 112, and 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum FSH concentration (mIU/mL)</measure>
    <time_frame>Days 2, 14, 28, 56, 84, 86, 112, and 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum PSA concentration (ng/mL)</measure>
    <time_frame>Days 2, 14, 28, 56, 84, 86, 112, and 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of bone pain</measure>
    <time_frame>Days 2, 14, 28, 56, 54, 84, 86, 112, and 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma testosterone concentration (ng/mL) in PK population</measure>
    <time_frame>week 4 and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of hot flushes</measure>
    <time_frame>Days 0, 2, 14, 28, 56, 84, 86, 112, and 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma leuprolide concentrations (pg/mL) in PK population</measure>
    <time_frame>Days 2, 14, 28, 56, 84, 86, 112, and 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of urinary symptoms</measure>
    <time_frame>Days 2, 14, 28, 56, 54, 84, 86, 112, and 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of urinary pain</measure>
    <time_frame>Days 2, 14, 28, 56, 54, 84, 86, 112, and 168</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>leuprolide acetate administered by i.m. injection as two doses of 17 mg each during a period of 6 months (one dose every 3 months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leuprolide acetate</intervention_name>
    <description>17 mg i.m.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males 18 years of age, with histologically proven carcinoma of prostate, who might
             benefit from medical androgen deprivation therapy;

          -  life expectancy of at least 1 year;

          -  WHO/ECOG performance status of 0, 1, or 2;

          -  adequate renal function at screening as defined by serum creatinine &lt;= 1.6 times the
             upper limit of normal (ULN) for the clinical laboratory;

          -  adequate and stable hepatic function as defined by bilirubin &lt;= 1.5 times the ULN and
             transaminases (i.e. SGOT, SGPT) &lt;= 2.5 times the ULN for the clinical laboratory at
             screening;

          -  ability to comprehend the full nature and purpose of the study, including possible
             risks and side effects; ability to co-operate with the Investigator and to comply with
             the requirements of the entire study;

          -  signed written informed consent prior to inclusion in the study.

        Exclusion Criteria:

          -  Evidence of brain metastases, in the opinion of the Investigator, taking into account
             medical history, clinical observations and symptoms;

          -  evidence of spinal cord compression, in the opinion of the Investigator, taking into
             account medical history, clinical observations and symptoms;

          -  evidence of severe urinary tract obstruction with threatening urinary retention, in
             the opinion of the Investigator, taking into account medical history, clinical
             observations and symptoms;

          -  presence of any tumor in the immediate vicinity which could cause cord compression, in
             the opinion of the Investigator, taking into account medical history and clinical
             observations;

          -  excruciating, severe pain from extensive osseous deposits, in the opinion of the
             Investigator, taking into account medical history, clinical observations and symptoms;

          -  testosterone levels &lt;= 1.5 ng/mL at screening, locally determined at the laboratory of
             each clinical site;

          -  previous cancer systemic therapy such as chemotherapy, immunotherapy (e.g. antibody
             therapies, tumor-vaccines), biological response modifiers (e.g. cytokines) within 3
             months of baseline;

          -  previous hormonal therapy for treatment of prostate cancer, such as LHRH analogues
             (e.g. Lupron®, Zoladex®, etc.) (no wash-out allowed);

          -  previous treatment with AR-receptor blockers, such as Casodex®, Fugerel®, Megace®,
             Androcur®(no wash-out allowed);

          -  previous orchiectomy, adrenalectomy or hypophysectomy;

          -  previous prostatic surgery (e.g. radical prostatectomy, transurethral resection of the
             prostate (TUR-P) within 2 weeks prior to or after baseline;

          -  previous local therapy to the primary tumor with a curative attempt other than surgery
             (external beam radiotherapy, brachytherapy, thermotherapy, cryotherapy) within 2 weeks
             prior to or after baseline;

          -  any investigational drug within 5 half-lives of its physiological action or 3 months,
             whichever is longer, before baseline;

          -  administration of 5-α-reductase inhibitors (Proscar®, Avodart®, Propecia®) within 3
             months before baseline;

          -  over-the-counter (OTC) or alternative medical therapies which have an estrogenic or
             anti-androgenic effect (i.e., PC-SPES, saw palmetto, Glycyrrhiza®, Urinozinc®, DHEA)
             within the 3 months before baseline;

          -  hematological parameters (RBC, total and differential WBC count, platelet count,
             hemoglobin, hematocrit) outside 20% of the upper or lower limits of normal (ULN, LLN)
             for the clinical laboratory at screening;

          -  co-existent malignancy, according to the Investigator's opinion;

          -  uncontrolled congestive heart failure, myocardial infarction or a coronary vascular
             procedure (e.g. balloon angioplasty, coronary artery bypass graft) or significant
             symptomatic cardiovascular disease(s) within 6 months before baseline; resting
             uncontrolled hypertension: &gt;=160/100 mmHg) or symptomatic hypotension within 3 months
             before baseline;

          -  venous thrombosis within 6 months of baseline;

          -  uncontrolled diabetes (patients with uncontrolled diabetes need to compensate the
             metabolic disorder before treatment with LH-RH analogues);

          -  history of drug and/or alcohol abuse within 6 months of baseline;

          -  serious concomitant illness(es) or disease(s) (e.g., hematological, renal, hepatic,
             respiratory, endocrine, psychiatric) that may interfere with, or put patients at
             additional risk for, their ability to receive the treatment outlined in the protocol;

          -  patients on anticoagulative therapy including warfarin (Coumadin®) and heparin. Those
             patients on low dose low molecular weight heparin may be enrolled in the study;

          -  Abnormal coagulation studies (PT/PTT) at baseline.

          -  blood donations/losses within 2 months of baseline, apart from previous prostatic
             surgery patients (see exclusion 10);

          -  known hypersensitivity to GnRH, GnRH agonist, including any LHRH analogues, or any
             excipients of the study formulation;

          -  history of the following prior to the study:

               -  immunization (within 4 weeks of baseline);

               -  flu shots (within 1 week of baseline or 1 week prior to and after study drug
                  administration);

               -  anaphylaxis;

               -  skin disease which would interfere with injection site evaluation;

               -  dermatographism will be documented at screening and followed up while on
                  treatment.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Advanced Research Institute</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lawrenceville Urology</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudson Valley Urology</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Medical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Urologic Care</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Associates</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio Research, PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2008</study_first_submitted>
  <study_first_submitted_qc>February 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2008</study_first_posted>
  <disposition_first_submitted>August 30, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>September 7, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 9, 2010</disposition_first_posted>
  <last_update_submitted>September 7, 2010</last_update_submitted>
  <last_update_submitted_qc>September 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Claudio Savulsky/Director, Global Medical Affairs</name_title>
    <organization>GP Pharm S.A.</organization>
  </responsible_party>
  <keyword>prostate</keyword>
  <keyword>cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

